TrkA kinase inhibitors, compositions and methods thereof

US9815846B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Helen J. Mitchell · Richboro, US
• Mark E. Fraley · North Wales, US
• Andrew Cooke · Doylestown, US
• Craig A. Stump · Pottstown, US
• Yi-Heng Chen · Whippany, US
• Xu-Fang Zhang · Dresher, US
• Casey Cameron McComas · Phoenixville, US
• Kathy Schirripa · Quakertown, US
• Melody McWherter · Boyertown, US
• Swati P. Mercer · Philadelphia, US
• Kerim Babaoglu · Lansdale, US
• Dongfang Meng · Morganville, US
• Jane Yang Wu · Marlboro, US
• Ping Liu · Shanghai, CN
• Harold B. Wood · Westfield, US
• Jianming Bao · Scotch Plains, US
• Chun Sing Li · Shanghai, CN
• Qinghua Mao · Shanghai, CN
• Zhiqi Qi · Shanghai, CN

Key dates

• Filing date: Mar 23, 2015
• Grant date: Nov 14, 2017
• Expiry date: Mar 23, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D471/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention is directed to six membered heteroaryl benzamide compounds of formula (I), which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.